Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1842)	9/19/2007 10:55:51 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

SQNM Is up another 5% today. It had a presentation on Monday & is scheduled to have another one on Monday.<g> It announced yesterday the launch of its MassARRAY TYPER 4.0 genotyping software, which it claims, enhances data quality, simplifies workflow, and improves ease of use. bigcharts.marketwatch.com SQNM Has had double digit improvements on revenues for 4 consecutive Qs & has continued to trim its losses. The nearest important resistance is the Aug7 H at 5.73 & then th Dec.5 H at 6.24 But it still has plenty of room upstairs to run.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1842)	10/11/2007 8:41:11 AM
From: Jibacoa	Respond to of 3722

ARIA Is gaining in premarket what it lost AHs yesterday. Yesterday it traded for a while above its Sep 10 H of 5.16 but it closed at 5.13 bigcharts.marketwatch.com But today it shoud make a 3 months H & may get to test its resistance at the 5.50 level after some news.<g> bigcharts.marketwatch.com ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents Thursday October 11, 7:30 am ET Agreement Further Highlights Therapeutic Value of ARIAD's Novel mTOR Inhibitor CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA - News) today announced that it has entered into a non-exclusive license agreement with ICON Medical Corp., an emerging cardiovascular medical device company, to develop and commercialize drug-eluting stents that deliver ARIAD's novel mTOR inhibitor, deforolimus, to prevent restenosis of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty. Inhibitors of mTOR block the wound-healing response to arterial injury that leads to restenosis. As part of the agreement, ARIAD will receive an equity stake in ICON, up to $27 million in payments based on achievement of certain clinical, regulatory and commercial milestones for two products and royalties on worldwide sales of all ICON medical devices delivering deforolimus. ICON will be responsible for the development and commercialization of these medical devices, and ARIAD will supply deforolimus to ICON for use in these devices. Additional terms were not disclosed. ARIAD has retained the right to enter into one additional non-exclusive license agreement, in addition to the licenses granted to ICON and Medinol Ltd., to develop and commercialize medical devices delivering deforolimus for use in vascular disease. "ICON is one of the most innovative and promising medical device companies with broadly applicable technologies," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "ICON's design and manufacturing capabilities have led to highly differentiated stent platforms and bioabsorbable polymer formulations that should enable its deforolimus-eluting stents to provide substantial benefit to patients with coronary and peripheral vascular disease. This agreement further enables ARIAD to focus on developing deforolimus in multiple cancer indications with our partner, Merck & Co., while maximizing the drug's potential non-oncology applications." The proprietary metal alloy (Nuloy(TM)) developed by ICON permits the manufacture of stents with extremely thin struts, yet without sacrificing radial strength. The Nuloy coronary stent system can be readily delivered to target vessels and positioned in difficult-to-reach vascular lesions, without compromising radiopacity (density) or durability of the stent. The Nuloy bare-metal stent has successfully completed its first-in-humans clinical trial. This platform will form the basis for ICON's initial deforolimus-eluting stent for use in coronary arteries. "We are delighted with the opportunity to work together with the ARIAD team. Having access to a well-characterized and broadly studied drug for use in drug-eluting stents should allow ICON to move ahead expeditiously in the development of our portfolio of innovative cardiovascular products for coronary and peripheral vascular disease," said Jay Yadav, M.D., chairman of ICON. President and chief executive officer of ICON, Jack Merritt added, "The combination of the Nuloy stent platform and deforolimus should provide interventional cardiologists with breakthrough treatment options in this growing patient population." Snip ARIA still has some room to run, but don't expect for it to go from 13 to 40 in one day as it did in Feb 2000. Those were other days.<g> bigcharts.marketwatch.com Bernard